Cure: FDA approves tablet form of blood cancer treatment

UC expert says more patients may potentially benefit from approval

Following positive results of clinical trials, the Food and Drug Administration recently approved a tablet version of a drug called Calquence for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and previously treated relapsed or refractory mantle cell lymphoma (MCL).

The drug was previously approved in capsule form, but the tablet form is able to be given to patients who are also taking drugs that reduce gastric acid.

"Patients with blood cancers like chronic lymphocytic leukemia and mantle cell lymphoma are often older and may face multiple medical conditions that may need intervention, including acid reflux or peptic ulcer disease,” John Byrd, MD, University of Cincinnati Cancer Center member, Gordon and Helen Hughes Taylor Endowed Chair and professor in the Department of Internal Medicine in UC's College of Medicine and a UC Health physician, told the publication Cure. “This provides another option for some patients with chronic lymphocytic leukemia and relapsed or refractory mantle cell lymphoma, enabling more patients to potentially benefit from this treatment.”

Read the Cure article.

Featured photo of John Byrd, MD. Photo/University of Cincinnati.

Related Stories


Vox: How fake AI images can expand your mind

March 31, 2023

Seeing is believing, to the mind. In a Vox article on the impact of AI-generated imagery, UC's Tony Chemero, a philosopher and cognitive scientist, is cited as saying that technology has the potential to expand the mind. The article comes at a time when leading tech influencers are asking for a pause on the development of AI.


Political interests cause inefficiencies in insurance

March 31, 2023

Research by a University of Cincinnati professor illustrates how insurance markets are broken, Massachusetts Institute of Technology economist Amy Finkelstein said during a Freakonomics Radio Book Club discussion.

Debug Query for this